Phosphodiesterase inhibitors for the management of lower urinary tract symptoms in men without benign prostatic hyperplasia: a systematic review
PDE5-Is, especially tadalafil, are effective and well-tolerated for non-BPH LUTS in men, offering advantages beyond urinary symptom relief, including sexual function preservation and pain reduction. These potential effects should be further explored, particularly when erectile dysfunction (ED) or discomfort is present.
Authors
- Turki Aloufi
- Ahmad S Badawi (ORCID: https://orcid.org/0009-0007-2176-691X)
- Ghassan A. Barayan (ORCID: https://orcid.org/0009-0007-5864-4545)
- Emad Sabri Rajih
- Hazim Alnazawi
- Diaa Mohammed Farghal
- Meshari Almuways
- Sadeem Alhejaili
- Abdulaziz Bakhsh
- Ziyad Alrehaili
- Eyad Garah
- Abdulhadi Alharbi
- Ibtihal Khan
Institutions
- Umm al-Qura University (SA)
- Taibah University (SA)
- King Fahad Hospital Jeddah (SA)
Publication Details
- Journal
- Translational Andrology and Urology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.21037/tau-2025-aw-788
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00